Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 19.76B | 9.44%19.38B | -0.20%78.24B | -1.94%18.79B | -16.31%17.71B | -1.20%78.39B | 3.48%21.09B | -17.27%16.98B | 2.62%19.16B | 7.05%21.16B |
| Cost of revenue | 16.75B | 8.65%16.59B | -3.60%64.63B | -7.13%15.74B | -15.70%15.27B | 4.82%67.04B | 0.80%17.41B | -16.14%14.58B | 14.58%16.94B | 24.76%18.11B |
| Gross profit | 3.01B | 14.30%2.79B | 19.93%13.61B | 37.80%3.05B | -19.95%2.44B | -26.22%11.35B | 18.29%3.69B | -23.50%2.4B | -42.94%2.21B | -41.92%3.05B |
| Operating expense | 1.83B | 10.04%1.78B | 1.50%6.75B | 0.73%1.67B | -5.12%1.61B | 1.34%6.65B | -1.89%1.66B | 0.00%1.64B | -1.14%1.65B | 8.90%1.7B |
| Staff costs | ---- | ---- | -0.30%1.68B | ---- | ---- | -8.24%1.68B | ---- | ---- | ---- | ---- |
| Selling and administrative expenses | ---- | ---- | 8.99%1.98B | ---- | ---- | 1.62%1.81B | ---- | ---- | ---- | ---- |
| -Selling and marketing expense | ---- | ---- | -1.21%163M | ---- | ---- | -22.54%165M | ---- | ---- | ---- | ---- |
| -General and administrative expense | ---- | ---- | 10.01%1.81B | ---- | ---- | 4.90%1.65B | ---- | ---- | ---- | ---- |
| Research and development costs | ---- | ---- | -6.81%588M | ---- | ---- | 12.88%631M | ---- | ---- | ---- | ---- |
| Other operating expenses | ---- | ---- | -0.60%2.51B | ---- | ---- | 5.79%2.52B | ---- | ---- | ---- | ---- |
| Operating profit | 1.17B | 22.61%1.01B | 45.99%6.86B | 147.06%1.39B | -38.65%827M | -46.72%4.7B | 42.19%2.03B | -49.20%761M | -74.59%561M | -63.44%1.35B |
| Net non-operating interest income (expenses) | -143M | -4.40%-95M | -10.84%-368M | -31.43%-92M | -26.39%-91M | -3.11%-332M | -27.03%-94M | -23.08%-96M | 16.67%-70M | 16.28%-72M |
| Non-operating interest income | --1M | -5.45%52M | 5.16%224M | 9.43%58M | 10.00%55M | 30.67%213M | 14.58%55M | 27.91%55M | 39.47%53M | 47.06%50M |
| Non-operating interest expense | --144M | 0.68%147M | 8.62%592M | 21.95%150M | 19.67%146M | 12.37%545M | 22.13%149M | 24.79%151M | 0.82%123M | 1.67%122M |
| Net investment income | -52M | 0.00%57M | -3.60%134M | -66.13%63M | 1.79%57M | -72.42%139M | -23.61%-89M | -110.37%-14M | 186M | 56M |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | 0 | 0 | 0 | 487.50%517M | 0 | 0 | 132.88%340M | 177M | ||
| Income from associates and other participating interests | -684M | 39.00%-377M | 41.48%-1.1B | -107.35%-141M | 21.27%-618M | -198.27%-1.87B | -3,688.89%-646M | -145.44%-374M | -111.43%-68M | -267.02%-785M |
| Special income (charges) | -234M | -27.31%-317M | -22.66%-471M | 34.38%-84M | -134.91%-249M | 25.44%-384M | 149.41%42M | 21.95%-192M | -3.23%-128M | -76.67%-106M |
| Less:Other special charges | --234M | 27.31%317M | 22.66%471M | -34.38%84M | 134.91%249M | -25.44%384M | -149.41%-42M | -21.95%192M | 3.23%128M | 76.67%106M |
| Other non-operating income (expenses) | 132M | -600.00%-85M | -314.58%-309M | 0 | -45.16%17M | 332.26%144M | 109.09%10M | -25.00%6M | 504.17%97M | -51.56%31M |
| Income before tax | 192M | 437.93%196M | 63.35%4.75B | 23.29%1.13B | -108.98%-58M | -72.10%2.91B | 19.96%1.25B | -95.75%91M | -70.90%919M | -84.15%646M |
| Income tax | 221M | -33.98%171M | 212.58%1.6B | 13.71%282M | -52.48%259M | -158.01%-1.42B | -527.91%-2.32B | -59.59%99M | -61.90%248M | -46.36%545M |
| Net income | -29M | 107.89%25M | -27.39%3.14B | 26.64%851M | -417.00%-317M | -45.61%4.33B | 613.20%3.57B | -100.42%-8M | -73.20%672M | -96.73%100M |
| Net income continuous operations | ---29M | 107.89%25M | -27.35%3.15B | 26.83%851M | -413.86%-317M | -45.63%4.33B | 611.58%3.57B | -100.42%-8M | -73.23%671M | -96.70%101M |
| Noncontrolling interests | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Net income attributable to the company | -29M | 107.89%25M | -27.39%3.14B | 26.83%851M | -417.00%-317M | -45.53%4.33B | 614.63%3.57B | -100.37%-7M | -73.15%671M | -96.73%100M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -29M | 107.89%25M | -27.39%3.14B | 26.83%851M | -417.00%-317M | -45.53%4.33B | 614.63%3.57B | -100.37%-7M | -73.15%671M | -96.73%100M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -0.17 | 107.76%0.18 | -27.27%22.91 | 27.52%6.21 | -417.81%-2.32 | -42.15%31.5 | 597.31%25.94 | -100.31%-0.04 | -71.37%4.87 | -96.50%0.73 |
| Diluted earnings per share | -0.2303 | 107.76%0.18 | -27.27%22.91 | 27.28%6.1985 | -417.81%-2.32 | -42.15%31.5 | 626.94%25.94 | -100.40%-0.051 | -71.37%4.87 | -96.50%0.73 |
| Dividend per share | 0 | 0 | 22.22%11 | 33.33%4 | 0 | -47.06%9 | -33.33%6 | 0 | -62.50%3 | 0 |
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |